Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06506617
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
HCAPPED I HCAP-Pcr in Emergency Department
Sponsor:
None
Organization:
None
Study Overview
Official Title:
HCAPPED I HCAP - Pcr in Emergency Department Early Multiplex PCR on Respiratory Samples From Patients With Pneumonia A No-profit Observation Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HCAPPED-I
Brief Summary:
Prospective Observational Study on Diagnostic Procedure - Single-Center Non-Profit
A pilot study will be conducted on a prospective cohort of patients with HCAP Healthcare-Associated Pneumonia This study will be conducted on a single arm of patients No control group or randomization is planned
The use of syndromic molecular panels in pneumonias with risk factors for MDR multidrug-resistant pathogens such as in patients with HCAP has become common practice However the use of this tool is reserved for patients with severe forms of HCAP PIROgt2 at least moderate ARDS and respiratory failure requiring high-flow oxygen during sepsis 30 and it is not yet standardized by international guidelines The decision to use this tool or not is currently at the clinician39s discretion and is usually reserved for the severe forms mentioned above The study aims to determine if the early use of this tool has a real benefit on the management of antibiotic therapy for these patients in terms of therapeutic changes compared to corporate and international guidelines
Duration of patient enrollment 1 year Duration of the study 15 years
A pilot study will be conducted on a prospective cohort of patients with HCAP Healthcare-Associated Pneumonia This study will be conducted on a single arm of patients No control group or randomization is planned
The use of syndromic molecular panels in pneumonias with risk factors for MDR multidrug-resistant pathogens such as in patients with HCAP has become common practice However the use of this tool is reserved for patients with severe forms of HCAP PIROgt2 at least moderate ARDS and respiratory failure requiring high-flow oxygen during sepsis 30 and it is not yet standardized by international guidelines The decision to use this tool or not is currently at the clinician39s discretion and is usually reserved for the severe forms mentioned above The study aims to determine if the early use of this tool has a real benefit on the management of antibiotic therapy for these patients in terms of therapeutic changes compared to corporate and international guidelines
Duration of patient enrollment 1 year Duration of the study 15 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None